On October 28, biological drug and product manufacturer, Samsung BioLogics, successfully raised $2bn in what is the world’s largest healthcare sector IPO since Healthscope’s $2.1bn offering in 2014. The deal priced at the top of the range and is also South Korea’s largest IPO in 6 years.

As a trusted financial platform partner, Dealogic helped the bookrunners seamlessly execute the transaction through the DealManager network, who were also kept updated with real-time mobile access via Pulse.

Transaction Details

Issuer: Samsung BioLogics

Nationality: South Korea

Industry: Healthcare

Deal Value ($m): 1,969

Deal Type: IPO

Bookrunners: Korea Investment & Securities, Citi, NH Investment & Securities, JPMorgan, and Credit Suisse

Key Points

• World’s largest healthcare sector IPO since Healthscope raised $2.1bn in July 2014
• South Korea’s largest IPO since Samsung Life Insurance’s $4.4bn offering in April 2010; also the country’s third largest IPO on record
• Third largest IPO in Asia Pacific this year, following Postal Savings Bank of China ($7.6bn) and JR Kyushu ($4.0bn)
• Healthcare IPO volume of $12.1bn this year is down just 4% year-on-year, although more than half ($6.7bn) of issuance this year was priced in October alone
• South Korean ECM issuance has been the bright spot in Asia Pacific this year, with total ECM volume of $10.7bn up 17% year-on-year, compared to a wider regional decline of 11% over the same period

Top 3 global healthcare IPOs in 2016 YTD

1. Samsung BioLogics, $2.0bn | South Korea | Oct 2016
2. ConvaTec Group, $1.8bn | United Kingdom | Oct 2016
3. China Resources Pharmaceutical Group, $1.8bn | Hong Kong | Oct 2016

Top 3 South Korean IPOs on record

1. Samsung Life Insurance, $4.4bn | Insurance | Apr 2010
2. Lotte Shopping, $3.7bn | Retail | Jan 2006
3. Samsung BioLogics, $2.0bn | Healthcare | Oct 2016

For more information on why South Korea is Asia’s ECM bright spot, watch our video here.